Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ventripoint Announces TSXV Approval of Extension of Warrants and Clarifies Warrants Subject to Extension

V.VPT

(TheNewswire)



NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Toronto, Ontario / TheNewswire / March 14, 2019 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT, OTCQB:VPTDF) has received the approval of the TSX Venture Exchange (“TSXV”) in respect of the previously-announced extension of warrants issued in connection with a private placement of the Corporation on March 23, 2017 (the “Private Placement Warrants”). The warrants issued in connection with a shares-for-debt transaction of the Corporation on March 21, 2017 (the “Shares-for-Debt Warrants”) will not be amended.  

The Private Placement Warrants are amended as follows:

Date of Issuance

Number of Warrants Outstanding

Expiry Date

Amended Expiry Date

Exercise Price (not amended)

March 23, 2017

10,496,938

March 23, 2019

March 23, 2021

$0.50

The following Shares-for-Debt Warrants will not be amended:

Date of Issuance

Number of Warrants Outstanding

Expiry Date

Exercise Price

March 21, 2017

1,575,000

March 21, 2019

$0.50

For further information on the amendment of the Private Placement Warrants, please see the Corporation’s news releases dated March 6, 2019.

About Ventripoint Diagnostics Ltd.

Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.  The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. In particular, this news release contains forward-looking information relating to the proposed amendment of the Warrants. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation, including expectations and assumptions concerning the completion of the amendment of the Warrants. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Such factors may include the failure of the Corporation to successfully satisfy certain conditions in connection with the amendment of the Warrants and failure to complete the amendment of the Warrants. Other factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.  Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2019 TheNewswire - All rights reserved.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today